Genomic modifiers in Huntington’s disease

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Sep 16 / Springer Healthcare

Genomic modifiers in Huntington’s disease

Neuroscience Huntington's Disease EHDN-2022

Description

Galen Wright talks about the latest status of genomic modifiers for Huntington’s disease, why they are key to clinical prediction, and their potential as alternative therapeutic targets to huntingtin-lowering strategies.

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.